Sequoia Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.28M | Buy |
3,917
+522
| +15% | +$170K | 0.01% | 601 |
|
|
2025
Q1 | $917K | Buy |
3,395
+99
| +3% | +$26.7K | 0.01% | 644 |
|
|
2024
Q4 | $776K | Buy |
3,296
+167
| +5% | +$39.3K | 0.01% | 658 |
|
|
2024
Q3 | $861K | Sell |
3,129
-179
| -5% | -$49.2K | 0.01% | 589 |
|
|
2024
Q2 | $804K | Buy |
3,308
+398
| +14% | +$96.7K | 0.01% | 540 |
|
|
2024
Q1 | $435K | Sell |
2,910
-4,804
| -62% | -$718K | 0.01% | 731 |
|
|
2023
Q4 | $1.48M | Buy |
7,714
+4,911
| +175% | +$940K | 0.02% | 424 |
|
|
2023
Q3 | $496K | Sell |
2,803
-148
| -5% | -$26.2K | 0.01% | 526 |
|
|
2023
Q2 | $561K | Buy |
+2,951
| New | +$561K | 0.01% | 492 |
|
|
2023
Q1 | – | Sell |
-934
| Closed | -$222K | – | 838 |
|
|
2022
Q4 | $222K | Buy |
+934
| New | +$222K | 0.01% | 700 |
|